The aim of the study is to observe patients with Type 2 Diabetes on basal insulin alone or basal insulin with oral agents can be efficiently and safely started with meal time insulin using U100 rapid acting insulin analog and V-Go® Disposable Insulin Delivery Device (V-Go) using one of two dose titration algorithms to achieve improved A1C at 4 months.

This study addresses the informational needs of Primary Care Physicians with regard to providing insulin dosing and titration information utilizing a V-Go disposable insulin delivery device. We look to compare two treatment arms of insulin dosing and titration in patients with Type 2 insulin-dependent diabetes - a fixed dose titration arm, and an arm where 50% of the insulin dose is given at the largest meal of the day. This study will provide practical information on glycemic control, dose requirements and safety in patients with Type 2 diabetes on basal insulin with or without oral anti-diabetic agents who are being primarily managed in the primary care office.

Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:

• Age ≥ 21 and ≤80 at time of study enrollment
• Ability to read and understand English
• BMI ≥ 25 kg/m2
• Weight less than or equal to 300 pounds.
• A1C ≥8 but ≤12% (most recent value within 4 weeks of baseline visit)
• Currently using any basal insulin therapy (NPH, Levemir, Lantus) with total daily dose of 30 to 120 units, and where basal dose is greater than the patient's BMI #
• Willing to attend their physician's office for follow-up visits
• Willing and able to understand and sign a written informed consent form (ICF) indicating that they agree to participate and have been informed of all pertinent aspects of the study
• Must be willing to take and record at least 3 glucose measurements per time period (pre-breakfast, lunch, dinner and bed) per week.
• Willing to opt-in into Valeritas Customer Care so that they can receive device support and reminders throughout the study
• Most recent primary care office visit at one of the participating sites.

Exclusion Criteria:Patients presenting with any the following exclusion criteria will not be eligible for enrollment into the study:

• Patient with confirmed Type 1 diabetes and/or patients with a weight greater than 300 lbs.
• Diagnosis of an Autoimmune disease affecting metabolism
• Currently using GLP-1 medications
• Current (within the last 6 months) or planned use of insulin pump for diabetes management or the use of U500 insulin.
• Ongoing participation in any clinical study
• Pregnant, lactating or intending to become pregnant
• Current chronic systemic steroid use
• Prior V-Go use